Bicycle Therapeutics plc (BCYC)

24,58 -0,11 (-0,45%) Al cierre: 04:00PM EDT

Bicycle Therapeutics plc

Portway Building
Blocks A & B Granta Park Great Abington
Cambridge CB21 6GS
United Kingdom
44 1223 261 503
https://www.bicycletherapeutics.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 284

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Kevin Lee M.B.A., Ph.D.	CEO & Executive Director	1,35M	N/A	1968
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE	Co-Founder & Non-Executive Director	57,75k	N/A	1951
Ms. Alethia Rene Young	Chief Financial Officer	581,69k	N/A	1979
Dr. Santiago Arroyo M.D., Ph.D.	Chief Development Officer	916,98k	N/A	1960
Dr. Christian Heinis	Scientific Founder	N/A	N/A	N/A
Mr. Alistair Milnes	Chief Operating Officer	796,09k	N/A	1974
Mr. Travis Thompson	Senior VP, Chief Accounting Officer & Principal Accounting Officer	N/A	N/A	N/A
Dr. Michael Skynner B.sc. Ph.d., Ph.D.	Chief Technology Officer	881,01k	N/A	1969
Dr. Nicholas Keen Ph.D.	Chief Scientific Officer	N/A	N/A	1968
Mr. Zafar Qadir	General Counsel	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Gobierno corporativo

El ISS Governance QualityScore de Bicycle Therapeutics plc, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.